What Action Is DEA Taking To Codify the MAPA Amendments in Its Regulations?
To implement the requirements of MAPA, DEA is adding the new definitions of “drug product” and “valid prescription” at 21 CFR 1300.02, and updating § § 1310.03 and 1310.05 to reflect the revised reporting requirements for mail order distributions. Specifically, DEA is amending § 1310.05 to explicitly exempt from the reporting requirements the low-risk categories of mail order transactions previously listed. DEA also reserves the right to exempt, by regulation, from the reporting requirements any other quantity, method, or type of distribution of a specific listed chemical (or drug product containing it) or group of listed chemicals (or drug products containing them) determined by the Administrator to be unnecessary for the effective enforcement of the Controlled Substances Act. What Is the Effect of MAPA on the Public and on Industry? MAPA will not adversely impact the public’s access to pseudoephedrine and phenylpropanolamine products. The majority of the products purchased by the p
